SCHEMBL6736073

SCHEMBL6736073

CCCCCCOCC(CC(C)C)NC(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CTSK P43235 3/20 0.55
CAPN1 P07384 6/20 0.46
CAPN9 O14815 2/20 0.46
CTSB P07858 2/20 0.46
MAPK1 P28482 2/20 0.46
PLA2G2C Q5R387 7/20 0.46
CTSL P07711 1/20 0.42
CTSH P09668 1/20 0.42
CTSS P25774 1/20 0.42
CTSC P53634 1/20 0.42
CYP3A4 P08684 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
BLM P54132 1/20 0.42
PLA2G10 O15496 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736076 1.00 CTSK (0.55) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL6741359 0.86 CTSK (0.51) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL7211795 0.86 CTSK (0.51) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL6742223 0.85 CTSK (0.60) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL6738598 0.84 CTSK (0.58) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL6738594 0.84 CTSK (0.58) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL913603 0.83 CTSK (0.76) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL6735420 0.83 CTSK (0.76) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL7206790 0.83 CTSK (0.76) CTSKCAPN1CAPN9CTSBMAPK1
SCHEMBL913547 0.82 CTSK (0.74) CTSKCAPN1CAPN9CTSBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6689785-B2 USEFUL PARTICULARLY AS REMEDIES FOR BONE DISEASES AND ARTHRITIS NIPPON CHEMIPHAR CO., LTD. (JP) 2004-02-10 US disclosed
EP-1022276-B1 EPOXYSUCCINAMIDE DERIVATIVES NIPPON CHEMIPHAR CO (JP) 2003-05-28 EP disclosed
US-20020091131-A1 Epoxysuccinamide derivatives VELCURA THERAPEUTICS, INC. 2002-07-11 US disclosed
US-6387908-B1 BONE DISORDERS; ANTIARTHRITIC AGENTS NIPPON CHEMIPHAR CO., LTD. (JP) 2002-05-14 US disclosed
EP-1022276-A1 EPOXYSUCCINAMIDE DERIVATIVES NIPPON CHEMIPHAR CO., LTD. (JP) 2000-07-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091131-A1 Epoxysuccinamide derivatives NR0B1, NR2E1, NR4A1 CTSK 1317/4885CAPN1 3204/4885CAPN9 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.